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In this review, we discuss the available experimental evidences supporting the chemopreventive efficacy of nonsteroidal anti-
inflammatory drugs (NSAIDs) on colorectal cancer and the biological basis for their possible role as anticancer agents. Although the
comprehension of the mechanisms underlying the effects of these drugs on colon cancer cells is incomplete, research efforts in
identifying the biochemical pathway by which NSAIDs exert their chemopreventive effect have provided a rationale for the potential
use of NSAIDs alone or in combination with conventional and experimental anticancer agents in the treatment of colorectal cancer.
In this paper, we review three main issues: (i) the role of COX-2 in colon cancer; (ii) the common death pathways between NSAIDs
and anticancer drugs; and (iii) the biological basis for the combination therapy with COX-2 selective inhibitors and new selective
inhibitors of growth factor signal transduction pathways.
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ROLE OF COX-2 IN COLON CANCER
Colorectal cancer is the third most common cancer in the world,
and the second most common cause of cancer-related death.
Despite the development of new strategies of aggressive surgical
and adjuvant therapy, little progress has been made in the
successful management of advanced disease; therefore, much hope
is currently placed on chemoprevention.
A large body of evidence from epidemiological studies and
clinical trials in patients with the hereditary colon cancer
syndrome, familial adenomatous polyposis coli (FAP) indicates
that aspirin and related drugs, known as nonsteroidal anti-
inflammatory drugs (NSAIDs), which share the property of
inhibiting the cyclooxygenase (COX) enzyme, hinder the develop-
ment of colon cancer and perhaps other cancers as well.
COX is the rate-limiting enzyme for the synthesis of eicosanoids,
such as prostaglandins, from arachidonic acid. Two COX isoforms
have been identified: the constitutively expressed COX-1 and the
inducible COX-2. COX-1 is a housekeeping gene and has an
important role in protecting the gastroduodenal mucosa. The
COX-2 gene, an immediate-early response gene, is rapidly induced
in response to tumour promoters, cytokines, and growth factors
(DuBois et al, 1994; Di Popolo et al, 2000). NSAIDs may achieve
different degrees of inhibition of COX-1 and COX-2 and can be
grouped into selective and nonselective inhibitors of COX-2.
The development of COX-2-specific inhibitors, like celecoxib
and rofecoxib, drugs that maintain their anti-inflammatory
properties while preserving the biosynthesis of protective prosta-
glandins, further raised interest in this field. A large body of
research was therefore performed to clarify the relative involve-
ment of the two COX isoforms in colorectal carcinogenesis and the
role of COX-2-selective inhibitors as chemopreventive agents.
COX-2, but not COX-1, expression was found to be increased in
colorectal cancer (Eberhart et al, 1994): approximately 50% of
adenomas and 80–85% of adenocarcinomas showed increased
expression of COX-2. This observation was later confirmed by
other investigators. More recently, studies underlying the role of
COX-2 in colorectal carcinogenesis were performed in animal
models: a series of reports documented that COX-2 mRNA was
elevated both in chemically induced colon tumours and intestinal
tumours in experimental animal models, and that traditional
NSAIDs and new COX-2-selective inhibitors reduced the number
of polyps and tumour incidence (Gupta and Dubois, 2001).
Although these data indicate that COX-2 plays a wide role in
colorectal carcinogenesis and that its pharmacological inhibition
by NSAIDs is the central event in the chemoprevention of colon
cancer, the mechanisms involved are yet to be clarified. It is also
unclear how COX-2 elevation exerts its oncogenic effect at the
molecular level, but an expanding body of evidence indicates a
pivotal role of COX-2 elevation in the prevention of programmed
cell death, that is, apoptosis, a process by which damaged or
mutated cells in colonic mucosa are removed (Cao and Prescott,
2002).
COMMON DEATH PATHWAYS BETWEEN NSAIDS
AND ANTICANCER DRUGS
Today, the management of advanced colorectal cancer involves
mainly the use of chemotherapeutic drugs. For this purpose, 5-FU
or new compounds direct thymidylate synthase (TS) inhibitors like
raltitrexed and nolatrexed, or irinotecan (CPT-11) and oxaliplatin,
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Most of these current available cytotoxic drugs have well-
recognised intracellular macromolecular targets (i.e. TS for 5-FU,
toposisomerase 1 for CPT-11). However, the pattern and the extent
of cell damage induced by chemotherapy in human cancer cells
have been suggested to depend also on the pathway downstream
from drug–target interaction that, once triggered, will initiate
apoptosis (Canman et al, 1992). Apoptosis is a complicated
process and its proper execution programme requires the
coordinated activation and execution of several pathways. There
is emerging evidence both that the major target for anticancer
therapy is the induction of apoptotic cell death, and that resistance
to antitumour treatments relies on reduced sensitivity to apoptosis
induction. Hence, novel treatment approaches have tried to
overcome this kind of drug resistance by manipulating key
regulator proteins in apoptosis machinery (Nicholson, 2000).
Figure 1 summarises the major apoptotic pathway in mammalian
cells and the current recognised sites of interference of COX
inhibitors.
In order to understand the molecular mechanisms underlying
the chemopreventive effect of NSAIDs, a number of studies have
assessed the effect of NSAIDs on cell growth and apoptosis in
cultured colon cancer cells. We and others have shown that
nonselective and COX-2-selective inhibitors are able to inhibit cell
growth and induce apoptosis in colon cancer cells (Elder et al,
1997; Ricchi et al, 1997; Di Popolo et al, 2000).
This effect in vitro has been initially attributed to COX
inhibition and to the consequent reduction in prostaglandin levels.
On the other hand, an expanding literature shows a reduced role of
the prostaglandin pathway in the mechanism of action of NSAIDs
and new coxib (Song et al, 2002). In fact, several NSAIDs maintain
their properties also in COX-2-negative tumour cell lines and
independently from COX-2 expression levels (Elder et al, 1997)
and, between coxib, Vioxx, although exhibiting similar COX-2
selectivity and clinical efficacy for inflammatory indication with
respect to celecoxib, has little or no anticancer activity (Johnson
et al, 2001; Waskewich et al, 2002). Although the concentration of
NSAIDs required to show these effects in vitro is sometimes
higher than the amount required to inhibit prostaglandin
production and higher than that achievable in vivo, numerous
studies have clearly focused on the induction of apoptosis as
the mechanism for growth inhibition of colon cancer cells.
Interestingly, most of the death pathways affected by NSAIDs
are those involved in anticancer drug-induced apoptosis and
resistance (Figure 1).
In fact, high doses of aspirin were shown to antagonise the
survival signalling pathway controlled by the transcriptional factor
NF-kB (Kopp and Ghosh, 1994) through the inhibition and the
destruction of the activity of IKB kinase b (Yin et al, 1998), an
enzyme that activates the NF-kB pathway by phosphorylating the
inhibitory subunit of NF-kB (IkB). A similar effect on inhibition of
IKB kinase b activity was reported for sulindac (Yamamoto et al,
1999). On the other hand, one study reported that inhibition of NF-
kB through the adenoviral delivery of a modified form of IkBa
sensitised chemoresistant tumours to the apoptotic effect of the
antiblastic compound irinotecan (Wang et al, 1999).
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Figure 1 Molecular mechanisms that mediate the effects of NSAIDs and anticancer drugs on survival and apoptosis in colon cancer cells. Schematic
representation of cytokine, EGF-related growth factors and TRAIL ligand-dependent signal transduction pathways for survival and apoptosis. Stimulatory and
inhibitory effects are indicated by arrows and bars, respectively. Abbreviations: MAPK¼mitogen-activated protein kinase, MAPKK¼mitogen-activated
protein kinase kinase, JNK¼jun kinase, IkB¼inhibitor kinase B, NF-kB¼nuclear factor kappa B, COX¼cyclooxygenase, PI3K¼phosphatidylinositol 3
kinase.
NSAIDS in colorectal cancer
P Ricchi et al
804
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was mediated by the inhibition of the activation (phosphorylation)
of the antiapoptotic protein kinase AKT (Hsu et al, 2000). A related
study demonstrated that transfection of the constitutively active
akt cDNA in a human lung cancer cell (A549) resulted in the
reduction of the cytotoxic effect of topotecan, and concluded that
topotecan exhibited its toxic effects by downregulating the Akt
survival signalling pathway (Nakashio et al, 2000).
In eucaryotic cells, survival and apoptosis are often regulated by
relative level of members of the Bcl-2 family proteins. One study
reported that members of the Bcl-2 family of proteins in human
colon cancer cell lines were modulated by 5-FU and that the ratio
of the antiapoptotic protein bcl-xl to the proapoptotic protein bax
may be related to chemosensitivity (Nita et al, 1998). On the other
hand, the COX-2-selective inhibitors SC-58125 and NS-398 were
reported to sensitise colon and prostate cancer cells, respectively,
to apoptosis by downregulating the antiapoptotic protein bcl-2
(Liu et al, 1998). In addition, in a study performed in HCT 116
colorectal cancer cells, the proapoptotic protein bax had a pivotal
role both in 5-FU and sulindac-induced apoptosis, and several
NSAIDs could decrease the level of the antiapoptotic gene BCL-xl
(Zhang et al, 2000). Similarly, aspirin and indomethacin were
shown to induce apoptosis through upregulation of the proapop-
totic proteins bax and bak and activation of caspase 3 (Zhou et al,
2001).
Several evidences suggest that both TRAIL (tumour necrosis
factor-related apoptosis-inducing ligand) and FAS signalling
pathways are involved in chemotherapy-induced apoptosis, either
activating the initiator caspase 8 or at the level of downstream
effector caspase (caspases 3, 6, 7) activation (Petak and Houghton,
2001). In the NSAID field, it was reported that indomethacin and
sulindac sulphide induced apoptosis of human leukemic Jurkat
cells by a mechanism that required the Fas-associated death
domain (Han et al, 2001). Similarly, a recent paper demonstrated
that sulindac sulphide and the COX-2-selective inhibitor SC-0236
could induce apoptosis coupled with upregulation of DR5, caspase
8 activation, and Bid cleavage in HCT116 human colon cancer cells
(He et al, 2002). Thus, the common interference of anticancer
agents and NSAIDs with the apoptosis machinery and signalling,
independently from their COX inhibitory effect supports their use
either as a single agent or as modulators of the cell death signalling
pathway to potentiate or restore cytotoxic anticancer drug action.
The evidence of NSAID proapoptotic and growth inhibitory
effects prompted the evaluation of the in vitro effects of a
combination treatment with conventional anticancer drugs.
Synergistic effects were reported as early as in the 1980s. The
combination of indomethacin with methotrexate increased the
killing of cultured NC cells without providing an exhaustive
mechanism for this effect (Bennett et al, 1987). More recently, a
report performed the first extensive screen of commercially
available NSAIDs with anticancer drugs and discussed the
potential clinical benefits of such a combination (Duffy et al,
1998); the authors observed dose-dependent synergistic effects
among the two classes of drugs and concluded that this effect
occurred independently from COX inhibition. Further combina-
tion therapies were evaluated: either sulindac sulphide, a COX-1
and COX-2 inhibitor, or other compounds devoid of COX-
inhibitor property, in combination with paclitaxel and cisplatin,
produced synergistic activity against three NSCLC and SCLS cell
lines (Soriano et al, 1999). More recently, it was found that
nimesulide, a COX-2-selective inhibitor, at clinically achievable
concentration reduced the IC50 values of various anticancer agents
in a lung cancer line (Hida et al, 2000).
Further studies are needed to better evaluate the combination
therapy of cytotoxic drugs and new COX-2 inhibitors other than
celecoxib and rofecoxib in colorectal cancer cells to induce the
optimal apoptotic effect and to avoid reduction of anticancer drugs
activity in the case of concurrent administration. In fact, several
conventional NSAIDs and currently used COX-2 inhibitors are
mainly antiproliferative and may upregulate the cyclin-dependent
kinase inhibitors p27
Kip1 and p21
WAF1 (Hung et al, 2000; King and
Khalili, 2001), thus theoretically limiting the effectiveness of cell
cycle-dependent chemotherapeutic agents. In partial support of
this hypothesis, we have described that high doses of aspirin and
NS-398 were able to reduce CPT-11- and Vp-16-induced toxicity in
cultured colon cancer cells independently of their COXs isoform
profile expression (Ricchi et al, 2002).
A potential role for NSAIDs in an adjuvant setting can also be
hypothesised independently from their effects on cell growth and
survival. Several promising classes of noncytotoxic agent are under
intense investigation (Sobrero et al, 2000). Most of them target the
well-recognised series of steps involved in the process of
metastasis. Neoangiogenesis is a crucial event of tumorigenesis
and metastatic development, because neovascularisation is re-
quired for tumours to grow beyond 2–3mm in size. There is
mounting evidence that prostaglandins participate in angiogenesis,
regulating the production of proangiogenic factors such as
vascular endothelial growth factor (VEGF). Both COX-1 and
COX-2 are involved in tumour vascularisation, and COX-2
inhibitors can directly affect angiogenesis (Gately, 2000). A recent
observation suggested that angiogenesis was directly involved in
the biology of tumour dormancy and was associated with the risk
of recurrence after adjuvant therapy in breast cancer (Gasparini
et al, 2001). It was also found that angiogenic inhibitor TNP
inhibited tumour growth when administered following cyclophos-
phamide (Shusterman et al, 2001); the authors also documented
that TNP directly inhibited angiogenesis and increased apoptotic
index in treated tumours, particularly in the setting of minimal or
subclinical disease. Finally, a recent paper demonstrated that
NSAIDs were able to suppress PGE2- and PGI-mediated endothe-
lial-cell spreading and migration in vitro and fibroblast growth
factor-2-induced angiogenesis in vivo (Dormond et al, 2001).
Despite all the discussed evidences of NSAID interference at
different levels with tumour cell proliferation, survival, and
metastatic formation, only few reports are available in the
literature concerning the treatment of human clinical cancer by
NSAIDs. In 1994, Lundholm et al, in a randomised trial, treated
135 undernourished patients with metastatic solid tumours to
receive placebo, prednisolone, or indomethacin, until death.
Indomethacin-treated patients suffered less pain and had a
significant increase in survival (Lundholm et al, 1994). Survival
analysis from all patients treated with either indomethacin or
prednisolone demonstrated a significantly prolonged survival by
anti-inflammatory treatment compared with placebo treatment.
They did not observe any serious relevant side effect for
indomethacin treatment and propounded for indomethacin with
respect to prednisolone, based on the theoretically and experi-
mentally less catabolic and immunoattenuating effect of indo-
methacin on the host compared with glucocorticoids.
In 1996, Sinicrope et al conducted a phase I trial in 15 patients
who had failed prior 5-FU-based therapy (Sinicrope et al, 1996).
They administered sulindac (300mgday
 1) associated with the
same schedules of systemic 5-FU and per os levamisole used in
the intergroup adjuvant trial (450mgm
 2 5-FU+150mg daily
levamisole). Leukopenia was no more frequent than in patients
receiving 5-FU and levamisole in the intergroup adjuvant trial. All
toxic effects were reversible, and there were no chemotherapy-
related deaths. A partial response was seen in one patient, three
patients had disease stabilisation, and 10 patients progressed while
in the study. Uptill today, celecoxib has been successfully used in
randomised clinical trials only as a chemopreventive agent to treat
colorectal and duodenal polyps in FAP patients (Steinbach et al,
2000; Phillips et al, 2002); the two doses (100 and 400mg twice
daily) of celecoxib employed were well tolerated compared with
placebo, but in the groups of patients receiving the most effective
dose (400mg twice daily), one allergic reaction and a greater
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observed.
New trials are currently evaluating coxibs as single agents to
treat only other precancerous lesions and cancer that express COX-
2 in adjuvant settings (Thun et al, 2002). However, all data
discussed above may support the use of NSAIDs and new coxibs
for the treatment of cancer in combination with standard therapy
also independently from cancer cell COX-2 levels.
Phase I studies are needed to evaluate in vivo the optimal dose
and timing of conventional and new COX-2-selective NSAIDs in
combination with the currently used chemotherapy regimen for
subsequent use in phase II trials.
FURTHER ATTRACTIVE COMBINATION THERAPY
The recent development of inhibitors of biochemical pathways that
are altered in cancer cells has given rise to the possibility of
evaluating new combination treatment regimens. In colon cancer
cells, different growth factors such as EGF, IGFs have been
identified as positive regulators of cell growth. In particular, the
erb/HER pathway seems to play an important role in the
maintenance of neoplastic disease. As discussed above, the COX-
2 pathway is implicated in colorectal cancer biology and it appears
under the control of growth factor signal transduction in several
experimental systems (DuBois et al, 1994; Di Popolo et al, 2000).
Thus, it is a conceptually reasonable combination therapy that
targets simultaneously COX-2 and growth factor receptor path-
ways (Figure 1). Recently, both a specific monoclonal antibody
against Her-2/neu activity (Herceptin) and a selective EGFR-
tyrosine kinase inhibitor (Iressa) came into clinical practice in
cancer patients. The above molecules have been shown to
synergise in vitro and in animal models the effects of conventional
anticancer agents (Ciardiello et al, 2000). First, treatments based
on combination therapy with NSAIDs and compounds that target
other oncogenic pathways have been successfully tested in
chemopreventive settings: Torrance et al (2000) showed that
combination treatment of APCmin mice with sulindac and the
ErbB tyrosine kinase inhibitor EKI-569 resulted in synergistic
antitumour activity that leads to complete polyp prevention in half
of all treated mice. Then, DuBois and collaborators, in the field of
cancer therapy, clearly showed that the combination of celecoxib
and herceptin had additive effects against the HCA rectal
adenocarcinoma cell line in vitro and in xenograft, which leads
to the almost complete inhibition of tumour growth (Mann et al,
2001).
Thus, coadministration of a selective COX-2 inhibitor with a
tyrosine kinase inhibitor could enhance their single-agent anti-
cancer activity and should be evaluated as a therapy in vitro and in
colon cancer patients. At the moment, there are no trials designed
to evaluate any of the above-mentioned combinations in colon
cancer patients.
CONCLUSIONS
Since the cure rate for colorectal cancer is low, it is mandatory to
develop therapeutic strategies with less toxicity also for adjuvant
therapy. Several lines of evidence suggest that COX-2 inhibitors
not only counteract the development of malignant tumour at an
early stage and cause premalignant tumours to regress, but also
stimulate the death of established cancer cells. Therefore, COX-2 is
becoming an attractive target for therapeutic strategies in colo-
rectal cancer. The ability of NSAIDs and COX-2 inhibitors to
synergise with conventional anticancer drugs and to induce
apoptosis also independently from COX-2 expression in vitro
further encourages their use in clinical practice. In addition, COX
inhibitors are effective in reducing angiogenesis, supporting their
use also in adjuvant settings. Recent evidences indicate that COX-
2-selective inhibitors may also synergise with new inhibitors of the
growth factor signal transduction pathways. Taken together, all
this information provides a rationale for NSAIDs used alone or in
combination with chemotherapeutic agents within clinical trials in
colorectal cancer patients.
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